CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade Cortexyme, Inc. - CRTX CFD

0.7263
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0344
Long position overnight fee

Long position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 0.54-7.28
Average Volume (10 days) 6.92M
Average Volume (3 months) 27.45M
Market Cap 36.13M
P/E Ratio -100.00K
Shares Outstanding 36.13M
Revenue N/A
EPS -2.23
Dividend (Yield %) N/A
Beta 1.27
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 23, 2023 0.7263 0.0000 0.00% 0.7263 0.7263 0.7263
Jan 10, 2023 0.7263 0.0000 0.00% 0.7263 0.7263 0.7263
Dec 28, 2022 0.7263 0.0000 0.00% 0.7263 0.7263 0.7263
Dec 13, 2022 0.7263 0.0000 0.00% 0.7263 0.7263 0.7263
Nov 30, 2022 0.7263 0.0720 11.00% 0.6543 0.7263 0.6543
Nov 29, 2022 0.6608 -0.0270 -3.93% 0.6878 0.7013 0.6453
Nov 28, 2022 0.6973 0.0296 4.43% 0.6677 0.6973 0.6577
Nov 25, 2022 0.7093 -0.0022 -0.31% 0.7115 0.7155 0.7015
Nov 23, 2022 0.7189 0.0116 1.64% 0.7073 0.7189 0.6968
Nov 22, 2022 0.7293 0.0420 6.11% 0.6873 0.7436 0.6793
Nov 21, 2022 0.6993 -0.0250 -3.45% 0.7243 0.7343 0.6893
Nov 18, 2022 0.7243 0.0149 2.10% 0.7094 0.7243 0.6993
Nov 17, 2022 0.6893 -0.0080 -1.15% 0.6973 0.7093 0.6593
Nov 15, 2022 0.7493 0.0002 0.03% 0.7491 0.7659 0.7009
Nov 14, 2022 0.6723 -0.0969 -12.60% 0.7692 0.7692 0.6701
Nov 11, 2022 0.8065 0.0982 13.86% 0.7083 0.8293 0.7083
Nov 10, 2022 0.7442 0.0099 1.35% 0.7343 0.7615 0.7243
Nov 9, 2022 0.7213 -0.0875 -10.82% 0.8088 0.8092 0.7043
Nov 8, 2022 0.7992 -0.0400 -4.77% 0.8392 0.8393 0.7792
Nov 7, 2022 0.8582 0.0290 3.50% 0.8292 0.8691 0.8192

Cortexyme, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total revenue 0 0 0 0 0
Total Operating Expense 10.37 12.119 39.168 78.893 90.318
Selling/General/Admin. Expenses, Total 1.271 2.034 8.954 17.586 29.523
Research & Development 9.099 10.085 30.214 61.307 60.795
Operating Income -10.37 -12.119 -39.168 -78.893 -90.318
Interest Income (Expense), Net Non-Operating -1.865 -0.357 2.188 2.044 0.62
Net Income Before Taxes -12.235 -12.476 -36.98 -76.849 -89.945
Net Income After Taxes -12.235 -12.476 -36.98 -76.849 -89.945
Net Income Before Extra. Items -12.235 -12.476 -36.98 -76.849 -89.945
Total Extraordinary Items 0
Net Income -12.235 -12.476 -36.98 -76.849 -89.945
Income Available to Common Excl. Extra. Items -12.235 -12.476 -36.98 -76.849 -89.945
Income Available to Common Incl. Extra. Items -12.235 -12.476 -36.98 -76.849 -89.945
Diluted Net Income -12.235 -12.476 -36.98 -76.849 -89.945
Diluted Weighted Average Shares 26.0133 26.0133 19.0319 29.1762 29.7185
Diluted EPS Excluding Extraordinary Items -0.47034 -0.4796 -1.94305 -2.63396 -3.02657
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.47034 -0.4796 -1.94305 -2.63396 -3.02657
Other, Net -0.247
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 0 0 0 0 0
Total Operating Expense 23.313 21.783 21.677 23.544 21.863
Selling/General/Admin. Expenses, Total 6.489 7.064 7.639 8.331 9.106
Research & Development 16.824 14.719 14.038 15.213 12.757
Operating Income -23.313 -21.783 -21.677 -23.544 -21.863
Interest Income (Expense), Net Non-Operating 0.227 0.16 0.128 0.105 0.072
Net Income Before Taxes -23.086 -21.754 -21.706 -23.399 -21.641
Net Income After Taxes -23.086 -21.754 -21.706 -23.399 -21.641
Net Income Before Extra. Items -23.086 -21.754 -21.706 -23.399 -21.641
Net Income -23.086 -21.754 -21.706 -23.399 -21.641
Income Available to Common Excl. Extra. Items -23.086 -21.754 -21.706 -23.399 -21.641
Income Available to Common Incl. Extra. Items -23.086 -21.754 -21.706 -23.399 -21.641
Diluted Net Income -23.086 -21.754 -21.706 -23.399 -21.641
Diluted Weighted Average Shares 29.5549 29.5874 29.7674 29.962 30.1345
Diluted EPS Excluding Extraordinary Items -0.78112 -0.73525 -0.72919 -0.78095 -0.71815
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.78112 -0.73525 -0.72919 -0.78095 -0.71815
Other, Net -0.131 -0.157 0.04 0.15
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total Current Assets 7.537 72.584 106.056 137.862 111.673
Cash and Short Term Investments 7.343 71.716 99.864 133.82 106.802
Cash 7.343 11.259 4.074 35.69 40.27
Cash & Equivalents 0 11.815 46.155 16.151 15.954
Short Term Investments 0 48.642 49.635 81.979 50.578
Prepaid Expenses 0.141 0.766 5.504 3.348 3.376
Other Current Assets, Total 0.053 0.102 0.688 0.694 1.495
Total Assets 7.718 72.877 124.37 189.466 133.228
Property/Plant/Equipment, Total - Net 0.122 0.283 1.334 1.101 1.428
Property/Plant/Equipment, Total - Gross 0.166 0.378 1.617 1.716 2.387
Accumulated Depreciation, Total -0.044 -0.095 -0.283 -0.615 -0.959
Other Long Term Assets, Total 0.059 0.01 0.217 0.039 0.194
Total Current Liabilities 1.763 1.457 8.892 16.996 14.222
Accounts Payable 0.517 0.495 3.075 3.555 4.911
Accrued Expenses 1.246 0.962 5.817 13.441 9.311
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 10.82 1.457 8.892 17.204 14.642
Total Long Term Debt 7.171 0 0 0 0
Long Term Debt 7.171 0
Other Liabilities, Total 1.886 0 0.208 0.42
Total Equity -3.102 71.42 115.478 172.262 118.586
Redeemable Preferred Stock 17.178 104.046 0
Common Stock 0.009 0.009 0.027 0.029 0.03
Additional Paid-In Capital 0.06 0.239 185.196 318.574 355.234
Retained Earnings (Accumulated Deficit) -20.349 -32.825 -69.805 -146.654 -236.599
Other Equity, Total 0 -0.049 0.06 0.313 -0.079
Total Liabilities & Shareholders’ Equity 7.718 72.877 124.37 189.466 133.228
Total Common Shares Outstanding 26.0133 26.0133 26.8694 29.5432 30.0744
Long Term Investments 16.763 50.464 19.933
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 149.885 135.843 119.427 111.673 96.353
Cash and Short Term Investments 147.035 129.95 114.412 106.802 91.524
Cash 24.569 5.744 8.357 40.27 27.403
Cash & Equivalents 38.246 47.049 36.6 15.954 32.361
Short Term Investments 84.22 77.157 69.455 50.578 31.76
Prepaid Expenses 2.293 5.455 4.52 3.376 2.784
Other Current Assets, Total 0.557 0.438 0.495 1.495 2.045
Total Assets 174.522 161.39 147.416 133.228 116.13
Property/Plant/Equipment, Total - Net 0.878 1.886 1.655 1.428 0.573
Property/Plant/Equipment, Total - Gross 1.579 2.674 2.53 2.387 1.569
Accumulated Depreciation, Total -0.701 -0.788 -0.875 -0.959 -0.996
Long Term Investments 23.72 23.516 26.141 19.933 19.175
Other Long Term Assets, Total 0.039 0.145 0.193 0.194 0.029
Total Current Liabilities 17.867 18.537 14.154 14.222 9.71
Accounts Payable 2.845 7.193 2.88 4.911 3.731
Accrued Expenses 15.022 11.344 11.274 9.311 5.979
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 18.038 19.31 14.764 14.642 9.75
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.171 0.773 0.61 0.42 0.04
Total Equity 156.484 142.08 132.652 118.586 106.38
Common Stock 0.029 0.03 0.03 0.03 0.03
Additional Paid-In Capital 326.006 333.427 345.751 355.234 365.096
Retained Earnings (Accumulated Deficit) -169.74 -191.494 -213.2 -236.599 -258.24
Other Equity, Total 0.189 0.117 0.071 -0.079 -0.506
Total Liabilities & Shareholders’ Equity 174.522 161.39 147.416 133.228 116.13
Total Common Shares Outstanding 29.5759 29.6558 29.8673 30.0744 30.1496
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Net income/Starting Line -12.235 -12.476 -36.98 -76.849 -89.945
Cash From Operating Activities -9.827 -11.695 -33.277 -50.818 -62.932
Cash From Operating Activities 0.045 0.051 0.188 0.332 0.344
Non-Cash Items 1.903 1.12 1.611 15.472 30.93
Cash Interest Paid 0.001 0.001
Changes in Working Capital 0.46 -0.39 1.904 10.227 -4.261
Cash From Investing Activities -0.077 -46.754 -17.747 -52.431 58.952
Capital Expenditures -0.077 -0.212 -0.055 -0.052 -0.18
Other Investing Cash Flow Items, Total 0 -46.542 -17.692 -52.379 59.132
Cash From Financing Activities 7.75 75.928 77.366 118.876 6.808
Issuance (Retirement) of Stock, Net 0 75.678 77.925 118.91 6.808
Issuance (Retirement) of Debt, Net 7.75 0.25 -0.559 -0.034 0
Net Change in Cash -2.154 17.479 26.342 15.627 2.883
Foreign Exchange Effects 0.055
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -23.086 -44.84 -66.546 -89.945 -21.641
Cash From Operating Activities -13.61 -31.172 -48.514 -62.932 -16.091
Cash From Operating Activities 0.086 0.173 0.26 0.344 0.038
Non-Cash Items 7.285 14.371 22.238 30.93 9.375
Changes in Working Capital 2.105 -0.876 -4.466 -4.261 -3.863
Cash From Investing Activities 31.643 37.267 38.033 58.952 13.413
Capital Expenditures -0.037 -0.136 -0.136 -0.18 -0.005
Other Investing Cash Flow Items, Total 31.68 37.403 38.169 59.132 13.418
Cash From Financing Activities 0.441 1.113 5.818 6.808 0.622
Issuance (Retirement) of Stock, Net 0.441 1.113 5.818 6.808 0.622
Net Change in Cash 18.474 7.208 -4.634 2.883 -2.16
Issuance (Retirement) of Debt, Net 0 0 0
Foreign Exchange Effects 0.029 0.055 -0.104
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Lamond (David A.) Individual Investor 10.1955 3683658 1634720 2022-01-31
EPIQ Capital Group, LLC Investment Advisor 5.6924 2056669 -1218879 2022-09-30 LOW
Dominy (Stephen S) Individual Investor 3.9791 1437674 763 2022-01-31
Lynch (Casey C) Individual Investor 3.2676 1180580 -120000 2022-01-31
Two Sigma Investments, LP Hedge Fund 2.6494 957229 -63818 2022-09-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.4135 872006 84018 2022-09-30 LOW
Pfizer Inc Corporation 1.6607 600000 -1456377 2021-12-31 MED
Federated Hermes MDTA LLC Investment Advisor/Hedge Fund 1.4255 515041 -13523 2022-09-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.3779 497835 30092 2022-09-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.3536 489073 489073 2022-09-30 MED
Millennium Management LLC Hedge Fund 1.2676 457991 112582 2022-09-30 HIGH
Low (Philip S) Individual Investor 1.2602 455309 455309 2022-05-19
Renaissance Technologies LLC Hedge Fund 0.9251 334225 54726 2022-09-30 HIGH
Pacific Heights Asset Management, LLC Investment Advisor 0.8995 325000 0 2022-09-30 LOW
Burleson & Company, LLC Investment Advisor 0.8412 303918 43769 2022-09-30 LOW
Thye (Dirk) Individual Investor 0.7775 280911 280911 2022-05-19
Lowe (Christopher P) Individual Investor 0.7335 265000 175000 2022-03-03 LOW
J.P. Morgan Securities LLC Research Firm 0.6392 230937 -334793 2022-09-30 MED
BNP Paribas Securities Corp. North America Research Firm 0.5737 207267 -78256 2022-09-30 MED
Smith (Karen L) Individual Investor 0.5389 194690 194690 2022-05-19 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Profit/Loss

Cortexyme Inc. Company profile

About Cortexyme Inc

Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

269 East Grand Ave
94080

Income Statement

  • Annual
  • Quarterly

News

Federal Reserve Building in Washington, DC

Central Bank Week: Fed, BOE, and ECB meeting previews - USD, EUR, GBP, S&P 500

A lookahead at possible Fed, BOE, and ECB meeting outcomes and market reactions.

14:40, 31 January 2023
Global Currencies.

FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis

USD, GBP/USD, EUR/USD forecasts for the week ahead.

16:33, 27 January 2023
Businessman representing recessionary, stagflation or inflation economies with graphs of the stock market as a concept of raw material. Financial world crisis concept.

WTI, Gold, Silver – commodities weekly forecast for the week ahead

Strength to strength in the commodity space, however, topside exhaustion begins to creep in

13:53, 27 January 2023
Rising stock market chart on a trading board background.

S&P 500, Nasdaq, DAX 40, Hang Seng technical update

Can the S&P 500 hold above its 2022 descending trend line?

12:44, 26 January 2023
photo illustration an Amazon logo seen displayed on a smartphone.

Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending

AMZN Q4 earnings preview and technical analysis

09:59, 25 January 2023

People also watch

Oil - Crude

79.39 Price
+0.610% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0049%
Overnight fee time 22:00 (UTC)
Spread 0.03

Natural Gas

2.74 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0742%
Short position overnight fee 0.0488%
Overnight fee time 22:00 (UTC)
Spread 0.005

XRP/USD

0.40 Price
-1.000% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00318

US100

12,072.10 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0179%
Short position overnight fee 0.0070%
Overnight fee time 22:00 (UTC)
Spread 1.8

Market analysis

Benjamin Franklin’s face on a $100 bill

USD forecast: DXY slides in risk-off market sentiment

17:16, 30 January 2023
A large Amazon logo displayed on the side of an Amazon building

Amazon stock forecast: Where next for AMZN amid massive layoffs?

17:55, 23 January 2023
Australian dollar bills

Australian dollar forecast: Will AUD outperform in 2023?

17:49, 20 January 2023

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading